Document:

Exhibit 10.1

 

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 240.24b-2

 

	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	1. CONTRACT
    ID CODE	PAGE    OF    PAGES
	 	 	1	     24

	2.  AMENDMENT/MODIFICATION NO.	3.  EFFECTIVE
    DATE	4.  REQUISITION/PURCHASE REQ. NO.	5.  PROJECT NO. (if applicable)
	0014	See
    Block 16C	OS111895	 

	6.  ISSUED
    BY	CODE	ASPR-BARDA	7. ADMINISTERED BY (If other than Item 6)

        
	CODE	ASPR-BARDA02
	ASPR-BARDA

        200 Independence
        Ave., S.W.

        Room 640-G

        Washington DC
        20201
	ASPR-BARDA

        330 Independence
        Ave, S.W., Rm G640

        Washington DC
        20201

	8.  NAME
    AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)	x	9A.  AMENDMENT
    OF SOLICITATION NO.	 
	 

                                                                                  CHIMERIX, INC. 1377270

        CHIMERIX, INC.      2505
        MERIDIAN P

        2505 MERIDIAN PKWY STE
        340

        DURHAM NC 277135246
	 	 	 
	9B.  DATED
    (SEE ITEM 11)	 
	 	 	 
	x	10A. MODIFICATION OF CONTRACT/ORDER
        NO.

        HHSO100201100013C
	 
	 	 	 
	10B.
    DATED (SEE ITEM 13)	 
	CODE
         1377270	FACILITY
    CODE	 	02/16/2011	 

	11.  THIS
    ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	 ̈	The
    above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers                         ̈  is
    extended.                                       
     ̈ is not extended Offers must acknowledge receipt of this amendment prior
    to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items
    8 and 15, and returning __________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of
    the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers.
    FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE
    SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted,
    such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this
    amendment, and is received prior to the opening hour and date specified.

 

	12. ACCOUNTING AND APPROPRIATION
        DATA (if required)                                            Net
        Increase:                                       $5,000,000.00

        2013.199202.25106

	13.  THIS
    ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS.  IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM
    14.
	CHECK ONE	A.     THIS
    CHANGE ORDER IS ISSUED PURSUANT TO:  (Specify authority)  THE CHANGES SET FORTH IN ITEM 14 ARE
    MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
	 
	 	B.      THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
	 	 
	 	C.      THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	 	 
	x	D.
                                                                                                    OTHER
                                                                                               (Specify type of modification
                                                                                               and authority)

        Bilateral:
        Mutual Agreement of the Parties

         

	E.  IMPORTANT:            Contractor                     ̈  is
    not.              x  is
    required to sign this document and return          1        
    copies to the issuing office.

	14.  DESCRIPTION
    OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

	Tax
                                                  ID Number:             33-0903395

        DUNS Number:       121785997

        A.          The
        purpose of this modification is to exercise Option 1 under CLIN 0002 of the contract in the amount of

        Total Estimated Cost:
        $[...***...]

        Total Fixed Fee: $[...***...]

        Total Estimated Cost Plus
        Fixed Fee: $5,000,000.00

        The total period of performance
        of Option 1 CLIN 0002 under the contract is from 1 June 2013 through 31 May 2014.

        Continued ...

	Except as provided herein,
    all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full
    force and effect.

	15A.  NAME
    AND TITLE OF SIGNER (Type or print)	16A.  NAME
    AND TITLE OF CONTRACTING OFFICER (Type or print)
	Michael
    Rogers, Chief Development Officer	ETHAN
    J. MUELLER
	15B.  CONTRACTOR/OFFEROR	15C.  DATE SIGNED	16B.  UNITED
    STATES OF AMERICA	16C.  DATE
    SIGNED
	   /s/
        Michael Rogers                                       

        (Signature
        of person authorized to sign)
	5/29/13	                   /s/Ethan
        J. Mueller                      

        (Signature
        of Contracting Officer)
	5/30/13

         

	NSN 7540-01-152-8070	 	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	 	Prescribed by GSA 
	 	 	FAR (48 CFR) 53.243

 

***Confidential Treatment Requested

 

    	 

    	 

    

 

	CONTINUATION
    SHEET	REFERENCE
                                                                                                                                                                  NO.
                                                                                                                                                                  OF
                                                                                                                                                                  DOCUMENT
                                                                                                                                                                  BEING
                                                                                                                                                                  CONTINUED

        HHSO100201100013C/0014
	PAGE   OF     PAGES
	2	      24

	NAME
        OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	ITEM NO.

        (A)
	SUPPLIES/SERVICES

        (B)
	QUANTITY

        (C)
	UNIT

        (D)
	UNIT PRICE

        (E)
	AMOUNT

        (F)

	 	1.This
        modification hereby results in an increase in the total amount of the contract from $30,955,542.00 by $5,000,000.00 to
        $35,955,542.00 as well as the following:

         

        Total Estimated
        Cost of the Contract: From $[...***...] By $[...***...] To $[...***...]

         

        Total Fixed
        Fee of the Contract: From $[...***...] By $[...***...] To $[...***...].

         

        Total Estimated
        Cost Plus Fixed Fee of the Contract: From $30,955,542.00 By $5,000,000.00 To $35,955,542.00.

         

        2.Block
        15G of the SF 26, the amount of $30,955,542.00 shall be changed to $35,955,542.00. In Block 14 of the SF 26, the following
        CAN Number is added:

         

        Appropriation
        Year: 2013, Object Class: 25106, CAN# 1992002 $5,000,000.00

         

        3.As
        a result, Attachment 1, Statement of Work dated 19 June 2012, under PART III, LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS,
        SECTION J – LIST OF ATTACHMENTS is hereby deleted and replaced with the attached Statement of Work dated 23 May
        2013.

         

        4.The
        incorporation of the attached Statement of Work (SOW) changes in the paragraph above also result in the incorporation
        of the attached changes into the contract into WBS Milestones/Deliverables and Technical Deliverables and Contract Milestones
        and Go/No Go Decision Gates dated 24 May 2013 under Articles F.2. Deliverables.

         

        5.Under
        Article B.4. PROVISIONS APPLICABLE TO DIRECT COSTS, b. Travel Costs, 1. Travel, a. is deleted and replaced with the following:

         

        a.Total
        expenditures for domestic travel (transportation, lodging, subsistence, and incidental expenses) incurred in direct performance
        of this contract shall not exceed $[...***...] during the base segment/CLIN 0001 and $[...***...] during Option Period
        1/CLIN 0002 without the prior written approval of the Contracting Officer.

         

        6.The
        first and second sentences in Article G.7. INDIRECT COST RATES of the contract are replaced with the following:

         

        The following
        rates will be utilized for billing purposes during both the base period/CLIN 0001 and Option 1/CLIN 0002 ONLY.

         

        FY 11 (Retroactive
        Adjustment base period/CLIN 0001 ONLY) – Fringe Benefits at [...***...]% and Indirect at [...***...]%.

         

        FY 12 and FY
        13 (Retroactive Adjustment and Billing, base period/CLIN 0001 ONLY and Billing, Option 1/CLIN 0002 ONLY) – Fringe
        Benefits at [...***...]% and Indirect at [...***...]%.

         

        7.This
        modification does not change the scope, the period of performance nor the Continued...

         

         

         

         

         

         
	 	 	 	 

 

***Confidential
Treatment Requested

 

    	 

    	 

    

  

	CONTINUATION
    SHEET	REFERENCE
        NO. OF DOCUMENT BEING CONTINUED

        HHSO100201100013C/0014
	PAGE   OF     PAGES
	3	      24

	NAME
        OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	ITEM NO.

        (A)
	SUPPLIES/SERVICES

        (B)
	QUANTITY

        (C)
	UNIT

        (D)
	UNIT PRICE

        (E)
	AMOUNT

        (F)

	 	total
                                                                         amount of the base segment/CLIN 0001 under this contract
                                                                         and this modification does not change the scope, the
                                                                         period of performance nor the total amount of option
                                                                         segments 2, 3 and 4 under this contract. This modification
                                                                         does not authorize the performance of option segments
                                                                         2, 3 and 4 under this contract.

         

        B.All
        other terms and conditions contract number HHSO100201100013C remain unchanged.

         

        Delivery:
        05/31/2014

        Delivery
        Location Code: HHS

        HHS

        200
        Independence Avenue, SW

        Washington
        DC 20201 US

         

        Appr.
        Yr.: 2013 CAN: 1992002 Object Class: 25106

        FOB:
        Destination

        Period
        of Performance: 02/16/2011 to 05/31/2014

         

        Change Item
        2 to read as follows (amount shown is the obligated amount):

         
	 	 	 	 
	2	[...***...]	 	 	 	 

        5,000,000.00

	 	Reports
                                                                         and Other Data Deliverables.

                                                                         Obligated Amount: $5,000,000.00

         

        

         

         

         
	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336-(4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 53.110

 

***Confidential
Treatment Requested

 

    	 

    	 

    

BARDA Broad Agency Announcement (BAA)

(CBRN-BAA-10-100-SOL-00012)

Advanced Research and Development of Chemical,
Biological, Radiological, and

Nuclear Medical Countermeasures

DEVELOPMENT OF CMX-001 FOR THE TREATMENT
OF SMALLPOX

 Topical Area of Interest No. 3,
Antimicrobial Drugs

 

Contractual Statement of Work

 

		1.	PREAMBLE

 

Independently and not as an
agency of the Government, the Contractor shall be required to furnish all the necessary services, qualified personnel, material,
equipment, and facilities, not otherwise provided by the Government, as needed to perform the Statement of Work submitted in response
to the BARDA Broad Agency Announcement (BAA) CBRN-BAA-10-100-SOL-00012.

 

In accordance with FAR 52.243-2,
Changes-Cost Reimbursement (Alt. V), the Government reserves the right to modify the milestones, progress, schedule, budget, or
to add or delete deliverables, process, or schedules if the need arises. Because of the nature of this research and development
(R&D) contract and the complexities inherent in this and prior programs, at designated milestones the Government will evaluate
whether work should be redirected, removed, or whether schedule or budget adjustments should be made.

 

		1.0	Overall Objectives and Scope

 

The overall objective of this
contract is to advance the development of CMX-001 as a broad-spectrum therapeutic antiviral for the treatment of smallpox infections
and dsDNA viruses. The scope of work for this contract includes preclinical, clinical and manufacturing development activities
that fall into the following areas: non-clinical efficacy studies; clinical activities; manufacturing activities; and all associated
regulatory, quality assurance, management, and administrative activities. The Research and Development (R&D) effort for the
antiviral will progress in specific stages that cover the base performance segment and four (4) option segments as specified in
this contract. The Contractor must complete specific tasks required in each of the five discrete work segments. The scope of work
has been broken into the following five phases which are discrete work segments:

 

		I.	[...***...]
                                                                                                        

		II.	[...***...]

		III.	[...***...]

		IV.	[...***...]

		V.	[...***...]

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

		2.	PHASE I. [...***...]

 

Research
and development of CMX-001 for the treatment of smallpox and dsDNA viruses to include the following activities: [...***...].
The contractor shall carry out the following tasks and subtasks and in accordance with an agreed upon Integrated Master Schedule
and Integrated Master Plan (defined in 2.1.8 and 2.1.9 below) which shall further detail the conduct of the specific tasks and
subtasks.

 

		2.1	Program Management

 

The Contractor shall provide
for the following as outlined below and in the contract deliverables list (Article F.2):

 

		2.1.1	The overall management,
                                                                        integration and coordination of all contract activities,
                                                                        including a technical and administrative infrastructure
                                                                        to ensure the efficient planning, initiation, implementation,
                                                                        and direction of all contract activities;

 

		2.1.2	A Principal Investigator
                                                                        (PI) responsible for project management, communication,
                                                                        tracking, monitoring and reporting on status and progress,
                                                                        and modification to the project requirements and timelines,
                                                                        including projects undertaken by subcontractors; The contract
                                                                        deliverables list (reference), identifies all contract
                                                                        deliverables and reporting requirements for this contract.

 

		2.1.3	Project Manager(s) with
                                                                        responsibility for monitoring and tracking day-to-day
                                                                        progress and timelines, coordinating communication and
                                                                        project activities; costs incurred; and program management;
                                                                        The contract deliverables list (reference), identifies
                                                                        all contract deliverables and reporting requirements for
                                                                        this contract.

 

		2.1.4	A BARDA Liaison with responsibility
                                                                        for effective communication with the Project Officer and
                                                                        Contracting Officer.

 

		2.1.5	Administrative and legal
                                                                        staff to provide development of compliant subcontracts,
                                                                        consulting, and other legal agreements, and ensure timely
                                                                        acquisition of all proprietary rights, including IP rights,
                                                                        and reporting all inventions made in the performance of
                                                                        the project.

 

		2.1.6	Administrative staff with
                                                                        responsibility for financial management and reporting
                                                                        on all activities conducted by the Contractor and any
                                                                        subcontractors.

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

		2.1.7	Contract Review Meetings.

		2.1.7.1	The Contractor shall participate
                                                                        in regular meetings to coordinate and oversee the contract
                                                                        effort as directed by the Contracting and Project Officers.
                                                                        Such meetings may include, but are not limited to, meeting
                                                                        of the Contractors and subcontractors to discuss clinical
                                                                        manufacturing progress, product development, product assay
                                                                        development, scale up manufacturing development, clinical
                                                                        sample assays development, preclinical/clinical study
                                                                        designs and regulatory issues; meetings with individual
                                                                        contractors and other HHS officials to discuss the technical,
                                                                        regulatory, and ethical aspects of the program; and meeting
                                                                        with technical consultants to discuss technical data provided
                                                                        by the Contractor.

		2.1.7.2	The Contractor shall participate
                                                                        in teleconferences every two weeks between the Contractor
                                                                        and subcontractors and BARDA to review technical progress.
                                                                        Teleconferences or additional face-to-face meetings shall
                                                                        be more frequent at the request of BARDA.

		2.1.8	Integrated Master Schedule

		2.1.8.1	Within 30 calendar days
                                                                        of the effective date of the contract, the Contractor
                                                                        shall submit a first draft of an updated Integrated Master
                                                                        Schedule in a format agreed upon by BARDA to the Project
                                                                        Officer and the Contracting Officer for review and comment.
                                                                        The Integrated Master Schedule shall be incorporated into
                                                                        the contract, and will be used to monitor performance
                                                                        of the contract. Contractor shall include the key milestones
                                                                        and Go/No Go decision gates. The 1MS for the period of
                                                                        performance will be mutually agreed upon at the PMBR

		2.1.9	Integrated Master Plan

		2.1.9.1	Work Breakdown Structure:
                                                                        The Contractor shall utilize a WBS template agreed upon
                                                                        by BARDA for reporting on the contact. The Contractor
                                                                        shall expand and delineate the Contract Work Breakdown
                                                                        Structure (CWBS) to a level agreed upon by BARDA as part
                                                                        of their Integrated Master Plan for contract reporting.
                                                                        The CWBS shall be discernable and consistent. BARDA may
                                                                        require Contractor to furnish WBS data at the work package
                                                                        level or at a lower level if there is significant complexity
                                                                        and risk associated with the task.

		2.1.9.2	GO/ NO-GO Decision Gates:
                                                                        The Integrated Master Plan outlines key milestones with
                                                                        “Go/No Go” decision criteria (entrance and
                                                                        exit criteria for each phase of the project). The project
                                                                        plan should include, but not be limited to, milestones
                                                                        in manufacturing, non-clinical and clinical studies, and
                                                                        regulatory submissions.

		2.1.9.3	Earned Value Management
                                                                        System Plan: Subject to the requirements under HHSAR Clause
                                                                        352.234-4, the Contractor shall use principles of Earned
                                                                        Value Management System (EVMS) in the management of this
                                                                        contract. The Seven Principles are:

		I.	Plan all work scope for the program to completion.

  

    	 

    	 

    

 

		II.	Break down the program work
                                                                    scope into finite pieces that can be assigned to a responsible
                                                                    person or organization for control of technical, schedule,
                                                                    and cost objectives.

		III.	Integrate program work scope,
                                                                     schedule, and cost objectives into a performance measurement
                                                                     baseline plan against which accomplishments may be measured.
                                                                     Control Changes to the baseline.

		IV.	Use actual cost incurred and
                                                                    recorded in accomplishing the work performed.

		V.	Objectively assess accomplishments
                                                                   at the work performance level.

		VI.	Analyze significant variances
                                                                    from the plan, forecast impacts, and prepare an estimate at
                                                                    completion based on performance to date and work to be performed.

		VII.	Use earned value information
                                                                     in the company’s management processes.

 

Elements of EVMS shall be applied
to all Cost Plus Fixed Fee CLINs as part of the Integrated Master Project Plan, the Contractor shall submit a written summary
of the management procedures that it will establish, maintain and use to comply with EVMS requirements.

 

		2.1.10	Decision Gate Reporting:
                                                                         On completion of a stage of the product development,
                                                                         as defined in the agreed upon Integrated Master Schedule
                                                                         and Integrated Master Plan, the Contractor shall prepare
                                                                         and submit to the Project Officer and the Contracting
                                                                         Officer a Decision Gate Report that contains (i) sufficient
                                                                         detail, documentation and analysis to support successful
                                                                         completion
                                                                         of the stage according to the predetermined qualitative
                                                                         and quantitative criteria that were established for Go/No
                                                                         Go decision making; and (ii) a description of the next
                                                                         stage of product development to be initiated and a request
                                                                         for approval to proceed to the next stage of product
                                                                         development.

 

		2.1.11	Risk Management Plan:
                                                                         The Contractor shall develop a risk management plan within
                                                                         90 days of contract award highlighting potential problems
                                                                         and/or issues that may arise during the life of the contract,
                                                                         their impact on cost, schedule and performance, and appropriate
                                                                         remediation plans. This plan should reference relevant
                                                                         WBS elements where appropriate. Updates to this plan
                                                                         shall be included every three months (quarterly) in the
                                                                         monthly Project Status Report.

  

    	 

    	 

    

 

		2.1.12	Performance Measurement
                                                                         Baseline Review (PMBR): The Contractor shall submit a
                                                                         plan for a PMBR to occur within 90 days of contract award.
                                                                         At the PMBR, the Contractor and BARDA shall mutually
                                                                         agree upon the budget, schedule and technical plan baselines
                                                                         (Performance Measurement Baseline).
                                                                         These baselines shall be the basis for monitoring and
                                                                         reporting progress throughout the life of the contract.
                                                                         The PMBR is conducted to achieve confidence that the
                                                                         baselines accurately capture the entire technical scope
                                                                         of work, are consistent with contract schedule requirements,
                                                                         are reasonably and logically planned, and have adequate
                                                                         resources assigned. The goals of the PMBR are as FOLLOWS:

 

		I.	Jointly assess areas such as
                                                                   the Contractor’s planning for complete coverage of the
                                                                   SOW, logical scheduling of the work activities, adequate resources,
                                                                   and identification of inherent risks

		II.	Confirm the integrity of the
                                                                    Performance Measurement Baseline (PMB)

		III.	Faster the use of EVM as
                                                                     a means of communication

		IV.	Provide confidence in the
                                                                    validity of Contractor reporting

		V.	Identify risks associated with
                                                                   the PMB

		VI.	Present any revised PMBs for
                                                                    mutual agreement

		VII.	Present an Integrated Master
                                                                     Schedule: The Contractor shall deliver an initial program
                                                                     level Integrated Master Schedule (IMS) that rolls up all
                                                                     time-phased WBS elements down to the activity level. This
                                                                     IMS shall include the dependencies that exist between tasks.
                                                                     This IMS will be agreed to and finalized at the PMBR. DI-MGMT-81650
                                                                     may be referenced as guidance in creation of the IMS (see
                                                                     http://www.acq.osd.mil/pm/).

		VIII.	Present the Risk Management
                                                                      Plan

 

		2.1.13	Deviation Request: During
                                                                         the course of contract performance, in response to a
                                                                         need to change IMS activities as baselined at the PMBR,
                                                                         the Contractor shall submit a Deviation Report. This
                                                                         report shall request a change in the agreed-upon IMS
                                                                         and timelines. This report shall include: (i) discussion
                                                                         of the justification/rationale for the proposed change;
                                                                         (ii) options for addressing the needed changes from the
                                                                         agreed upon timelines, including a cost-benefit analysis
                                                                         of each option; and (iii) recommendations for the preferred
                                                                         option that includes a full analysis and discussion of
                                                                         the effect of the change on the entire product development
                                                                         program, timelines, and budget.

	 	 	 
		2.1.14	Monthly and Annual Reports:
                                                                         The Contractor shall deliver Project Status Reports on
                                                                         a monthly basis. The reports shall address the items
                                                                         below cross referenced to the WBS, SOW, IMS, and EVM:

		I.	Executive summary highlighting
                                                                   the progress, issues, and relevant activities in manufacturing,
                                                                   non-clinical, clinical, and regulatory;

  

    	 

    	 

    

 

		II.	Progress in meeting contract
                                                                    milestones, detailing the planned progress and actual progress
                                                                    during the reporting period, explaining any differences between
                                                                    the two and corrective steps;

 

		III.	Updated IMS;

		IV.	Updated EVM;

		V.	Updated Risk Management Plan
                                                                   (Every 3 months);

		VI.	Three month rolling forecast
                                                                    of planned activities;

		VII.	Progress of regulatory submissions;

		VIII.	Estimated and actual expenses;

 

		2.1.15	Data Management: The
                                                                         Contractor shall develop and implement data management
                                                                         and quality control systems/procedures, including transmission,
                                                                         storage, confidentiality, and retrieval of all contract
                                                                         data;

 

		2.1.15.1	Provide for the statistical
                                                                         design and analysis of data resulting from the research;

 

		2.1.15.2	Provide raw data or specific
                                                                         analyses of data generated with contract funding to the
                                                                         Project Officer, upon request.

	 	 	 
		2.2	Non-Clinical Toxicology

		2.2.1	N/A (no scope)

 

		2.3	Non-Clinical

		2.3.1	Develop and validate [...***...]
                                                                        to lower [...***...].

		2.3.2	[...***...]:
                                                                        Conduct [...***...]
                                                                        studies including [...***...]
                                                                        studies, [...***...],
                                                                        and [...***...]
                                                                        studies in [...***...].

		2.3.3	[...***...]

		2.3.3.1	Conduct [...***...]
                                                                        study in [...***...].

		2.3.3.2	Conduct [...***...]
                                                                        studies including [...***...]
                                                                        studies, [...***...]
                                                                        studies including [...***...]
                                                                        for CMX-001 and [...***...]
                                                                        in [...***...].

		2.3.4	Use of [...***...]
                                                                        as a CMX-001 Surrogate in [...***...]
                                                                        Studies.

		2.3.4.1	Dose [...***...]
                                                                        with [...***...]
                                                                        to identify the concentration of the [...***...]
                                                                        in [...***...]
                                                                        associated with [...***...]
                                                                        of [...***...].

		2.3.5	Scaling of [...***...]
                                                                        to [...***...]
                                                                        by conducting studies with [...***...]
                                                                        to determine [...***...]
                                                                        in [...***...].

		2.3.6	[...***...]
                                                                        determination of CMX001, [...***...]
                                                                        and [...***...]
                                                                        in the [...***...].

		2.3.7	Conduct [...***...]
                                                                        experiments to demonstrate [...***...]
                                                                        following effective [...***...]
                                                                        prior to [...***...].

		2.3.8	Conduct studies to optimize
                                                                        [...***...]
                                                                        in [...***...].

		2.3.9	Conduct CMX-001 [...***...]
                                                                        study in [...***...]
                                                                        at a dose of CMX001 equivalent or less than [...***...]
                                                                        with treatment beginning at the [...***...].

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

		2.4	Clinical

 

		2.4.1	Measurement of [...***...]
                                                                        levels in [...***...]
                                                                        and correlate the [...***...]
                                                                        levels to studies conducted in [...***...].

		2.4.2	Conduct expanded access
                                                                        protocol ([...***...]).

		2.4.3	Analyze data and provide
                                                                        a Final Report for [...***...]
                                                                        evaluation of CMX001 in patients ([...***...])

 

		2.5	Regulatory

 

		2.5.1	Engaging the FDA on a
                                                                        path to support the treatment of smallpox indication with
                                                                        CMX-001

		2.5.2	Preparing materials for
                                                                        and requesting, scheduling and participating in all meetings
                                                                        with the FDA, including meetings to review EUA and/or
                                                                        all other data packages;

		2.5.3	Providing BARDA with (i)
                                                                        the initial draft minutes and final draft minutes of any
                                                                        formal meeting with the FDA; (ii) final minutes of any
                                                                        informal meeting with the FDA;

		2.5.4	Obtain FDA concurrence
                                                                        on the feasibility of the proposed [...***...]
                                                                        with CMX001/[...***...]/[...***...]
                                                                        in the [...***...]
                                                                        ([...***...]),
                                                                        including FDA feedback on [...***...]
                                                                        and review of data for the first [...***...]
                                                                        enrolled in the [...***...]
                                                                        sub-study

		2.5.5	Develop and submit a revised
                                                                        [...***...]
                                                                        for CMX001 for Treatment of Smallpox, including [...***...]
                                                                        for FDA review and comment, and revise the [...***...]
                                                                        as requested by FDA

 

		2.6	CMC

 

		2.6.1	Validation of the [...***...]
                                                                        process: Validation of the process to demonstrate
                                                                        the [...***...]
                                                                        of a [...***...]
                                                                        of acceptable quality will be performed.

		2.6.2	Validation of the [...***...]
                                                                        process to produce [...***...]:
                                                                        Validation of the process to demonstrate the [...***...]
                                                                        of a [...***...]
                                                                        of acceptable quality will be performed.

 

		3.	PHASE II: [...***...]

 

Research
and development of CMX001 for the treatment of smallpox to include the following activities: [...***...].
The contractor shall carry out the following tasks and subtasks and in accordance with the agreed upon Integrated Master Schedule
and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

		3.1	Program Management (consistent
                                                                  with section 2.1)

 

		3.1.1	Program management scope
                                                                        in BASE year is consistent with program management scope
                                                                        in each option year.

 

		3.2	Non-Clinical toxicology

 

		3.2.1	N/A (no scope)

 

		3.3	Non-Clinical

 

		3.3.1	Quantify [...***...]
                                                                        concentrations in [...***...]
                                                                        from [...***...].

 

		3.3.2	Determine [...***...]
                                                                        for CMX001 in [...***...]
                                                                        in [...***...].

 

		3.3.3	Scaling of [...***...]
                                                                        to [...***...]
                                                                        – Review with BARDA and FDA the [...***...]
                                                                        generated to support scaling between [...***...]
                                                                        and [...***...]
                                                                        using [...***...]
                                                                        as well as comparisons of [...***...]
                                                                        in the [...***...].

 

		3.3.4	Determine [...***...]
                                                                        for CMX001 in [...***...]
                                                                        in [...***...].

 

		3.3.5	Conduct [...***...].

 

		3.3.6	Conduct [...***...]
                                                                        and [...***...]

 

		3.3.7	Chimerix will provide
                                                                        [...***...]
                                                                        for the [...***...]
                                                                        and [...***...]
                                                                        conducted under [...***...]

 

		3.4	Clinical

 

		3.4.1	N/A (No scope)

 

***Confidential
Treatment Requested

 

    	 

    	 

    

  

		3.5	Regulatory

 

		3.5.1	Engaging the FDA on a
                                                                        path to support the treatment of smallpox indication with
                                                                        CMX001

 

		3.5.2	Generating all necessary
                                                                        documentation for [...***...].
                                                                        [...***...]

 

		3.5.3	Preparing materials for
                                                                        and requesting, scheduling and participating in all meetings
                                                                        with the FDA, including meetings to review EUA (if needed)
                                                                        and/or all other data packages;

 

		3.5.4	Providing BARDA with (i)
                                                                        the initial draft minutes and final draft minutes of any
                                                                        formal meeting with the FDA relating to the smallpox program;
                                                                        (ii) final draft minutes of any informal meeting with
                                                                        the FDA relating to the smallpox program,

 

		3.6	CMC

 

		3.6.1	N/A (No scope)

 

		4.	PHASE III: [...***...]

 

Research
and development of CMX-001 for the treatment of smallpox and dsDNA viruses to include the following activities: [...***...].
The contractor shall carry out the following tasks and subtasks and in accordance with agreed upon Integrated Master Schedule
and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

		4.1	Program Management (Consistent
                                                                  with section 2.1)

 

		4.1.1	Program management scope
                                                                        in BASE year is consistent with program management scope
                                                                        in each option year.

 

		4.2	Non-toxicology

 

		4.2.1	N/A (no scope)

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

		4.3	Non-Clinical

		4.3.1	[...***...]
                                                                        studies: [...***...]
                                                                        will be conducted with the [...***...]
                                                                        of CMX001 identified in the [...***...]
                                                                        studies. [...***...]
                                                                        will be [...***...]
                                                                        to receive [...***...]
                                                                        beginning at the [...***...].
                                                                        These studies will include [...***...]
                                                                        and [...***...]
                                                                        as well as [...***...]
                                                                        including [...***...]
                                                                        in [...***...].
                                                                        The primary endpoint will be [...***...]

		4.3.2	[...***...]
                                                                        studies: This study will determine the [...***...]
                                                                        at the [...***...].
                                                                        [...***...]
                                                                        and [...***...]
                                                                        at
                                                                        the [...***...].
                                                                        The primary endpoint will be [...***...]

		4.3.3	Initiate [...***...]:
                                                                        Conduct [...***...]
                                                                        studies for [...***...].
                                                                        This study will determine the [...***...]
                                                                        at doses selected based on [...***...].
                                                                        [...***...]
                                                                        and [...***...].

 

		4.4	Clinical

		4.4.1	Phases I [...***...]
                                                                        study, If acceptable to FDA, the [...***...]
                                                                        database will be supplemented by a study in [...***...].
                                                                        The size of this study will be determined to ensure an
                                                                        adequate [...***...]
                                                                        database is available at the time of [...***...]

		4.4.2	[...***...]
                                                                        study. This study will [...***...]
                                                                        doses of CMX001 to [...***...]
                                                                        to determine if the [...***...]
                                                                        of CMX001 are comparable to those observed for
                                                                        [...***...],
                                                                        and to determine if any dose adjustment is necessary in
                                                                        [...***...].

 

		4.5	Regulatory

 

		4.5.1	Generating all necessary
                                                                        data and preparing documentation for [...***...]
                                                                        submissions to regulatory agencies;

 

		4.5.2	Preparing materials for
                                                                        and requesting, scheduling and participating in all meetings
                                                                        with the FDA, including meetings to review [...***...],
                                                                        EUA and/or all other data packages;

 

		4.5.3	Providing BARDA with (i)
                                                                        the initial draft minutes and final draft minutes of any
                                                                        formal meeting with the FDA; (ii) final draft minutes
                                                                        of any informal meeting with the FDA;

 

		4.5.4	Filing of [...***...]

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

		4.6	CMC

 

		4.6.1	Manufacture of [...***...]
                                                                        in sufficient quantities for use in non-clinical
                                                                        and late phase clinical studies. Develop [...***...].

 

		5.	PHASE IV: [...***...]

 

Research
and development of CMX-001 for the treatment of smallpox to include the following activities: [...***...].
[...***...] studies
and phase I [...***...]
study. The contractor shall carry out the following tasks and subtasks and in accordance with agreed upon Integrated Master Schedule
and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

		5.1	Program Management (Consistent
                                                                  with section 2.1)

 

		5.1.1	Program management scope
                                                                        in BASE year is consistent with program management scope
                                                                        in each option year.

 

		5.2	Non-Clinical toxicology

 

		5.2.1	N/A (no scope)

 

		5.3	Non-Clinical

 

		5.3.1	[...***...]
                                                                        studies. [...***...]
                                                                        will be randomized to receive [...***...]
                                                                        beginning at the [...***...].
                                                                        These studies will include [...***...]
                                                                        and [...***...]
                                                                        as well as [...***...]
                                                                        including [...***...].
                                                                        The primary endpoint will be [...***...]

 

		5.3.2	[...***...]
                                                                        Studies. This study will determine the [...***...]
                                                                        at the [...***...].
                                                                        [...***...]
                                                                        and [...***...]
                                                                        at the [...***...].
                                                                        The primary endpoint will be [...***...].
                                                                        If FDA requires a [...***...]
                                                                        in the [...***...]
                                                                        studies, the [...***...]
                                                                        study may not be needed.

 

		5.3.3	Conduct [...***...]
                                                                        Studies. This study will determine the [...***...]
                                                                        at the [...***...].
                                                                        [...***...]
                                                                        and [...***...]
                                                                        at the [...***...].

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

		5.4	Clinical

 

		5.4.1	Phase 3 development including
                                                                        [...***...]
                                                                        study, [...***...]
                                                                        study, phases II [...***...]
                                                                        study. A [...***...]
                                                                        study will be conducted to compare the [...***...]
                                                                        of CMX001 in [...***...]
                                                                        to [...***...].
                                                                        A [...***...]
                                                                        study will be conducted to compare the [...***...]
                                                                        of CMX001 when [...***...].
                                                                        A [...***...]
                                                                        study will be conducted to [...***...]
                                                                        to support an NDA.

 

		5.5	Regulatory

 

		5.5.1	Generating all necessary
                                                                        data and preparing documentation for NDA submissions to
                                                                        regulatory agencies;

		5.5.2	Preparing materials for
                                                                        and requesting, scheduling and participating in all meetings
                                                                        with the FDA, including meetings to review IND, EUA and/or
                                                                        all other data packages;

		5.5.3	Providing BARDA with (i)
                                                                        the initial draft minutes and final draft minutes of any
                                                                        formal meeting with the FDA; (ii) final draft minutes
                                                                        of any informal meeting with the FDA;

 

		5.6	CMC

 

		5.6.1	[...***...].
                                                                        [...***...]
                                                                        of the process to demonstrate the [...***...]
                                                                        of a [...***...]
                                                                        will be performed.

 

		6.	PHASE V: [...***...]

 

Research
and development of CM-X-001 for the treatment of smallpox to include the following activities: [...***...].
The contractor shall carry out the following tasks and subtasks and in accordance with an agreed upon Integrated Master Schedule
and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

		6.1	Program Management (Consistent
                                                                  with section 2.1)

		6.1.1	Program management scope
                                                                        in BASE year is consistent with program management scope
                                                                        in each option year.

 

		6.2	Non-Clinical toxicology

		6.2.1	N/A (no scope)

 

		6.3	Non-Clinical

		6.3.1	[...***...]
                                                                        Studies. This study replicates [...***...]
                                                                        if a [...***...]
                                                                        is necessary to achieve a [...***...]
                                                                        result.

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

		6.4	Clinical

 

		6.4.1	Compile [...***...].
                                                                        A database of [...***...]
                                                                        data collected from all CMX001 clinical studies,
                                                                        irrespective of [...***...],
                                                                        will be populated and analyzed in order to support an
                                                                        [...***...]
                                                                        for smallpox.

 

		6.5	Regulatory

 

		6.5.1	Generating all necessary
                                                                        data and preparing documentation for NDA submissions to
                                                                        regulatory agencies;

		6.5.2	Submitting NDA documentation
                                                                        to the FDA in a timely manner, consistent with timelines
                                                                        set out in the contract and by the FDA.

		6.5.3	Preparing materials for
                                                                        and requesting, scheduling and participating in all meetings
                                                                        with the FDA, including meetings to review IND, EUA and/or
                                                                        all other data packages;

		6.5.4	Providing BARDA with (i)
                                                                        the initial draft minutes and final draft minutes of any
                                                                        formal meeting with the FDA; (ii) final draft minutes
                                                                        of any informal meeting with the FDA;

 

		6.6	CMC

 

		6.6.1	[...***...].
                                                                        [...***...]
                                                                        of the process to demonstrate the [...***...]
                                                                        of a [...***...]
                                                                        will be performed.

 

		7.	Other
                                                                 Items

 

		7.1	Facilities, Equipment and
                                                                  Other Resources. (Contract: Section J)

 

The Contractor
shall provide equipment; facilities and other resources required for implementation of the SOW dated January 11, 2011 to comply
with all Federal and HHS regulations in:

 

		7.1.1	The [...***...]
                                                                        and use of [...***...];

		7.1.2	The acquisition, handling,
                                                                        storage and shipment of [...***...],
                                                                        including [...***...]
                                                                        required for working with the [...***...];

		7.1.3	The [...***...]
                                                                        of [...***...]
                                                                        under cGMP;

		7.1.3.1	The design and conduct
                                                                        of [...***...];
                                                                        and

		7.1.3.2	The conduct of [...***...]
                                                                        studies to determine [...***...]
                                                                        of [...***...]

 

		7.1.4	Design and conduct of [...***...]
under GCP.

 

***Confidential
Treatment Requestedm

 

    	 

    	 

    

 

REVISED MILESTONES ARTICLE F.2 DELIVERABLES

 

	Current

    Milestone #	Milestone
    Definition	Go
    Criteria	No-Go
    Criteria	Deliverable	WBS/SOW
    #	Segment
	1.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	2.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	3.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	4.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

***Confidential
Treatment Requested

 

    	1.

    	 

    

 

	5.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	6.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

	7.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	8.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	9.	No
    longer in development plan.	 	 	 	N/A	N/A
	10.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

	11.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	12.	No
    longer in development plan.	 	 	 	N/A	N/A
	13.	No
    longer in development plan.	 	 	 	N/A	N/A
	14.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	15.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

	16.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

	17.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	18.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	19.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	20.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

	21.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	22.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	23.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	24.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	25.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

	26.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	BCA
    MILESTONE	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	NEW
    OPTION 1 MILESTONE TO BE ADDED TO ARTICLE F.2 DELIVERABLES OF THE CONTRACT
	28.	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]	[...***...]
	 	 	 	 	 	 	 	 	 	 	 	 

***Confidential
Treatment RequestedExhibit 10.1

 

BONDER TONGUE LABORATORIES, INC.

 

INDEMNIFICATION AGREEMENT

 

THIS AGREEMENT is made
effective as of _________ __, _____, by and between BLONDER TONGUE LABORATORIES, INC., a Delaware corporation, for itself and on
behalf of its subsidiaries (the “Company”) and the undersigned _____________, serving as an officer and/or director
of the Company (the “Indemnitee”).

 

Background

 

The Indemnitee performs
valuable services for the Company in the capacity as an officer and/or director, and where applicable, an employee or agent of
the Company and various affiliated entities, and as a fiduciary with respect to certain employee benefit plans maintained by the
Company. The Company desires to encourage the continued performance of such services for and on behalf of the Company, and the
Indemnitee is willing to continue performing such valuable services notwithstanding the substantial increase in risk of personal
liability by reason of serving in such capacities for a publicly held company in consideration of the Company’s providing
the benefits set forth in this Agreement.

 

NOW, THEREFORE, in consideration
of the mutual premises and covenants contained herein, and intending to be legally bound, the parties agree as follows:

 

1.Indemnification
by the Company.

 

(a)The Company
shall indemnify and hold the Indemnitee harmless of, from and against any and all liabilities, claims, expenses (including reasonable
attorney’s fees), judgments and fines to the fullest extent as authorized or permitted under Section 145 of the Delaware
General Corporation Law (“DGCL”)as in effect on the date hereof, and to the extent any amendment to such section
or other applicable law may expand indemnification rights, to the full extent authorized or permitted by such section or other
applicable law as may be in effect from time to time; provided however that such indemnification shall not apply to expenses incurred
by the Indemnitee in a suit against the Company except for expenses incurred in an action brought in good faith to enforce his
rights under this Agreement. In the event that such statute is hereafter amended or modified in any fashion, no such modification
shall in any way limit or reduce the indemnification obligation of the Company hereunder.

 

(b)In addition,
the Company shall indemnify and hold the Indemnitee harmless of, from and against any and all liability, expenses (including attorneys’
fees), claims, judgments, fines and amounts paid in settlement, actually incurred in connection with any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or investigative (including but not limited to an
action by or in the right of the Company), to which the Indemnitee is, was or at any time becomes a party or is threatened to be
made a party, by reason of the fact that the Indemnitee is, was or at any time becomes a director or officer of the Company, or
is or was serving or at any time serves at the request of the Company as a director, officer, employee or agent of any other corporation,
partnership, joint venture, trust, enterprise or person of any nature whatsoever.

 

(c)It is the express
understanding of the parties hereto that, except as expressly limited in Sections 2 and 6 below, the Company shall provide indemnification
to the Indemnitee to the fullest extent as may be permissible under the laws and public policy of the State of Delaware, including,
without limitation, claims for money damages against the Indemnitee in respect of an alleged breach of fiduciary duty, to the fullest
extent permitted under Section 102(b)(7) of the DGCL as in existence on the date hereof. For the avoidance of doubt, this shall
include indemnification with respect to liabilities, claims, expenses (including reasonable attorney’s fees), judgments and
fees attributable to the Indemnitee’s services as a fiduciary (within the meaning of Section 3(21) of the Employee Retirement
Income Security Act of 1974, as amended) of one or more employee benefit plans maintained by the Company.

 

    	 

    	 

    

 

2.Exclusions From
Indemnification. Notwithstanding anything contained in Section 1 which may be construed to the contrary, the Company shall
not be obligated to indemnify the Indemnitee in any of the following circumstances:

 

(a)With respect
to conduct of the Indemnitee which is finally adjudged by a court to have been knowingly fraudulent, deliberately dishonest or
to have involved willful misconduct;

 

(b)In the event
that a judgment is rendered against the Indemnitee for an accounting of profits made from the purchase and sale of securities of
the Company in violation of the provisions of Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar
provisions of any federal or state law as may be hereinafter enacted, or amounts paid in settlement of any such claimed violation;

 

(c)In the event
that the aggregate losses to be indemnified hereunder, exclusive of insurance reimbursement with respect to directors’ and
officers’ liability insurance maintained by the Company from time to time, does not exceed $1,000; or

 

(d)In the event
that a court finally determines that such indemnification would violate public policy or is otherwise unlawful.

 

The parties acknowledge that the indemnification
provided hereunder is narrower in scope than the indemnification provided under Article III, Section 14 of the Company’s
by-laws. The Indemnitee consents to the limitations contained herein and agrees not to make any claim against the Company under
Article III of the by-laws or under the Company’s Certificate of Incorporation, for any indemnification with respect to the
matters set forth in this Section 2 or to the extent such indemnification would be inconsistent with the provisions of Section
6 hereof.

 

3.Insurance.
The Company agrees that for as long as the Indemnitee shall continue to serve the Company in any capacity, and for a period of
three years thereafter, the Company will use all reasonable efforts to acquire and maintain for the benefit of the Indemnitee valid,
binding and enforceable policies of directors’ and officers’ liability insurance and where appropriate, ERISA fiduciary
liability insurance providing coverage of at least $5 million. The Company shall not be required to maintain any such policies
if such insurance is not reasonably available, or if, in the reasonable judgment of the then directors of the Company, either (i)
the premium cost for such insurance is substantially disproportionate to the coverage available, or (ii) the coverage provided
is so limited by exclusions that there is insufficient benefit from such insurance.

 

4.Continuity.
The obligations of the Company under this Agreement shall continue at all times while the Indemnitee serves the Company in such
capacity, or continues to serve the Company as a director, officer, employee or agent of any other corporation, partnership, joint
venture, trust, enterprise or person of any nature whatsoever, and shall continue thereafter as long as the Indemnitee shall be
in any way subject to possible claim or threatened or pending action, suit or proceeding by reason of the fact that the Indemnitee
served the Company (or such other persons) in any such capacity.

 

5.Reimbursement
of Expenses. Incidental to the indemnification provided under Section 1 hereof, the Company shall reimburse the Indemnitee
for the reasonable out-of-pocket expenses incurred by the Indemnitee in connection with any action or matter as to which the Company
is obligated to provide indemnification under Section 1 hereof, upon receipt by the Company of a written undertaking from the Indemnitee
to repay such amounts if it shall ultimately be determined that he is not entitled to be indemnified by the Company under applicable
law. The Indemnitee agrees that he will reimburse the Company for all such expenses paid by the Company so advanced, including
any and all expenses of defending any civil or criminal action, suit or proceeding against the Indemnitee in the event and only
to the extent that it shall ultimately be determined that the Indemnitee is not entitled to be indemnified by the Company. The
Indemnitee’s expenses (including reasonable attorney’s fees) incurred in connection with successfully establishing
such Indemnitee’s right to indemnification and reimbursement of expenses, in whole or in part in any such proceedings or
otherwise, shall also be indemnified by the Company.

 

6.Notification
and Defense of Claims. Promptly after receipt by the Indemnitee of notice of any claim or the commencement of any action, suit
or proceeding, the Indemnitee will notify the Company of the commencement thereof. The failure to so notify the Company will not
relieve it from any obligation which it may have to the Indemnitee under this Agreement or otherwise except to the extent such
failure has materially impaired the ability of the Company to defend successfully such action or to minimize the economic exposure
resulting therefrom. With respect to each such action, suit or proceeding as to which the Indemnitee gives proper notice to the
Company hereunder, the following provisions shall be applicable.

 

    	2

    	 

    

 

(a)The Company
shall be entitled to participate in the defense thereof at its own expense.

 

(b)Except as otherwise
provided in this subsection (b) the Company will be entitled to assume the defense thereof with counsel reasonably satisfactory
to the Indemnitee. The Company shall give notice of its election to assume the defense of such action within thirty (30) days after
the commencement of the action or the date it receives notice thereof, whichever is later. Thereafter, the Company will not be
liable to the Indemnitee under this Agreement or otherwise for any legal or other expenses subsequently incurred by the Indemnitee
in connection with the defense thereof other than reasonable costs of investigation, or as otherwise provided in this subsection
(b). The Indemnitee shall have the right to employ personal counsel in such action, suit or proceeding, but the fees and expenses
of such counsel incurred after notice from the Company of its assumption of the defense thereof shall be at the sole expense of
the Indemnitee unless (A) the employment of counsel by the Director has been expressly authorized at such time by the Company,
(B) the Indemnitee shall have reasonably concluded that there may be a disabling conflict of interest between the Company and the
Indemnitee in the conduct of the defense of such action, or (C) the Company shall not in fact have employed counsel to assume the
defense of such action, and in each of such cases, the fees and expenses of counsel retained by the Indemnitee shall be paid by
the Company. The Company shall not be entitled to assume the defense of any action, suit or proceeding brought by or derivatively
on behalf of the Company, or as to which the Indemnitee shall have concluded as provided in clause (B) above that there may be
a disabling conflict of interest between the Company and the Indemnitee in the conduct of the defense of such action.

 

(c)The Company
shall not be liable for indemnification to the Indemnitee under this Agreement for any amounts paid in settlement of any action
or claim, which settlement is effected without the prior written consent of the Company. The Company shall not settle any action
or claim in any manner which would impose any penalty or limitation upon the conduct of the Indemnitee without the written consent
of the Indemnitee. Neither the Company nor the Indemnitee will unreasonably withhold his or its consent to any proposed settlement.

 

7Notices.
Any notice, request or other communication required or permitted to be given to the parties under this Agreement shall be in writing
and either delivered in person or sent by telecopy, telex, telegram, overnight mail or courier service, or certified or registered
mail, return receipt requested, postage prepaid, to the parties at the following addresses (or at such other addresses for a party
as shall be specified by like notice):

 

If to the Company:

 

Blonder Tongue Laboratories, Inc.

One Jake Brown Road

Old Bridge, New Jersey 08857

Attn: Board of Directors

Facsimile: 732 679-3259

 

With a copy to:

 

Stradley Ronon Stevens & Young

2005 Market Street, Suite 2600

Philadelphia PA 19103

Attn: Gary P. Scharmett, Esquire

Facsimile: 215 564-8120

 

 

If to Indemnitee:

 

To the address set forth under
Indemnitee’s

name on the signature page hereof.

 

    	3

    	 

    

 

8.General Terms
and Conditions.

 

(a)Each of the
provisions of this Agreement is a separate and distinct agreement and independent of each of the other provisions hereof. In the
event any provision shall be held to be invalid or unenforceable, such invalidity or unenforceability shall in no way impair or
affect the validity and enforceability of each other provision hereof.

 

(b)This Agreement
shall be interpreted and construed in accordance with the substantive laws of the State of Delaware without regard to the law of
conflicts.

 

(c)No amendment,
modification, termination or cancellation of this Agreement shall be effective unless in writing signed by both parties hereto.

 

(d)Except as expressly
provided in Section 2, the provisions for indemnification and advancement of expenses in this Agreement shall not be deemed exclusive
of any other rights which the Indemnitee may have under any provision of law, the Company’s Certificate of Incorporation
or by-laws, the vote of the Company’s stockholders or disinterested directors, or otherwise and the Indemnitee’s rights
hereunder shall continue after the Indemnitee has ceased acting as an agent of the Company. No amendment or alteration of the Company’s
Certificate of Incorporation or by-laws or any other agreement shall adversely affect the rights provided to the Indemnitee under
this Agreement.

 

(e)This Agreement
is binding upon the Indemnitee and the Company and their respective successors and assigns and in the case of the Indemnitee, also
such Indemnitee’s heirs and personal representatives.

 

IN WITNESS WHEREOF, the
Undersigned have executed this Agreement as of the day and year first written above.

 

 

 

	 	BLONDER TONGUE LABORATORIES, INC.
	 	 
	 	By: 	 
	 	 	James A. Luksch, Chief Executive Officer

 

	 	 	INDEMNITEE
	 	 	 
	Witness	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]